TGFB1 and cancer: Malignant cells achieve this switch through either the inactivation of their TGF-β receptors, or by selectively disabling the tumor-suppressive arm of this pathway, allowing cancer cells to use the TGF-β regulatory functions to their advantage by promoting immune tolerance [53].